Endocrine Therapy for Hormone Receptor-Positive Metastatic Breast Cancer: American Society of Clinical Oncology Guideline.
暂无分享,去创建一个
Lesley Fallowfield | Mohammad Jahanzeb | Debra L Barton | Rita S Mehta | James N Ingle | L. Fallowfield | H. Rugo | H. Burstein | J. Ingle | B. Fowble | S. Johnston | L. Korde | R. B. Rumble | H. Muss | M. Dickler | R. Mehta | M. Jahanzeb | Hope S Rugo | Hyman B Muss | Larissa A Korde | Harold J Burstein | Maura N Dickler | J. Khatcheressian | R Bryan Rumble | Erin Macrae | Hannah Klein Connolly | Barbara Fowble | Stephen R D Johnston | James L Khatcheressian | D. Barton | H. Connolly | E. Macrae | R. Rumble
[1] M. Cristofanilli,et al. Inhibition of EGFR, HER2, and HER3 signaling with AZD8931 in combination with anastrozole as an anticancer approach: Phase II randomized study in women with endocrine-therapy-naïve advanced breast cancer , 2016, Breast Cancer Research and Treatment.
[2] J. Baselga,et al. Abstract S6-01:PIK3CAstatus in circulating tumor DNA (ctDNA) predicts efficacy of buparlisib (BUP) plus fulvestrant (FULV) in postmenopausal women with endocrine-resistant HR+/HER2– advanced breast cancer (BC): First results from the randomized, phase III BELLE-2 trial: , 2016 .
[3] H. Rugo,et al. Cyclin-Dependent Kinase 4/6 Inhibitors for the Treatment of Breast Cancer: A Review of Preclinical and Clinical Data. , 2016, Clinical breast cancer.
[4] H. Rugo. Dosing and Safety Implications for Oncologists When Administering Everolimus to Patients With Hormone Receptor-Positive Breast Cancer. , 2016, Clinical breast cancer.
[5] L. Hernandez-Aya,et al. Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer: Turner NC, Ro J, André F, et al (Royal Marsden Hosp, London, UK; National Cancer Ctr, Goyang-si, South Korea; Inst Gustave Roussy, Villejuif, France; et al) N Engl J Med 373:209-219, 2015§ , 2016 .
[6] P. Goodwin. Obesity, insulin resistance and breast cancer outcomes. , 2015, Breast.
[7] S. Johnston. Enhancing Endocrine Therapy for Hormone Receptor-Positive Advanced Breast Cancer: Cotargeting Signaling Pathways. , 2015, Journal of the National Cancer Institute.
[8] R. Schiff,et al. ESR1 mutations—a mechanism for acquired endocrine resistance in breast cancer , 2015, Nature Reviews Clinical Oncology.
[9] M. Ellis,et al. The ALTERNATE trial: assessing a biomarker driven strategy for the treatment of post-menopausal women with ER+/Her2- invasive breast cancer. , 2015, Chinese clinical oncology.
[10] R. Bast,et al. Use of Biomarkers to Guide Decisions on Systemic Therapy for Women With Metastatic Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] M. Ellis,et al. Phase III trial evaluating the addition of bevacizumab to letrozole as first-line endocrine therapy for treatment of hormone-receptor positive advanced breast cancer: CALGB 40503 (Alliance). , 2015 .
[12] M. Ellis,et al. Abstract S2-02: The FERGI phase II study of the PI3K inhibitor pictilisib (GDC-0941) plus fulvestrant vs fulvestrant plus placebo in patients with ER+, aromatase inhibitor (AI)-resistant advanced or metastatic breast cancer – Part I results , 2015 .
[13] M. Ellis,et al. Abstract S6-04: Fulvestrant 500 mg versus anastrozole as first-line treatment for advanced breast cancer: Overall survival from the Phase II ‘FIRST’ study , 2015 .
[14] J. Robertson,et al. Abstract P1-13-02: Visceral metastases from hormone receptor positive breast cancer are as sensitive to endocrine therapy as non-visceral metastases , 2015 .
[15] C. Perou,et al. Defining breast cancer intrinsic subtypes by quantitative receptor expression. , 2015, The oncologist.
[16] S. Loibl,et al. Phase III trial evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for advanced breast cancer: the letrozole/fulvestrant and avastin (LEA) study. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] Fabrice André,et al. Rationale for targeting fibroblast growth factor receptor signaling in breast cancer , 2015, Breast Cancer Research and Treatment.
[18] M. Fernö,et al. Molecular subtype and tumor characteristics of breast cancer metastases as assessed by gene expression significantly influence patient post-relapse survival , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.
[19] Massimo Cristofanilli,et al. Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer. , 2015, The New England journal of medicine.
[20] Xin Huang,et al. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. , 2015, The Lancet. Oncology.
[21] E. Winer,et al. Endocrine therapy with or without inhibition of epidermal growth factor receptor and human epidermal growth factor receptor 2: a randomized, double-blind, placebo-controlled phase III trial of fulvestrant with or without lapatinib for postmenopausal women with hormone receptor-positive advanced brea , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] P. Neven,et al. Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2†. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.
[23] G. Hortobagyi,et al. Chemotherapy and targeted therapy for women with human epidermal growth factor receptor 2-negative (or unknown) advanced breast cancer: American Society of Clinical Oncology Clinical Practice Guideline. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] E. Winer,et al. Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer: American Society of Clinical Oncology clinical practice guideline. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] C. Porta,et al. Adverse event management in patients with advanced cancer receiving oral everolimus: focus on breast cancer. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.
[26] M. Piccart,et al. Incidence and time course of everolimus-related adverse events in postmenopausal women with hormone receptor-positive advanced breast cancer: insights from BOLERO-2 , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.
[27] John M S Bartlett,et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. , 2014, Archives of pathology & laboratory medicine.
[28] Didier Verhoeven,et al. Final Overall Survival: Fulvestrant 500mg vs 250mg in the Randomized CONFIRM Trial , 2013, Journal of the National Cancer Institute.
[29] John M S Bartlett,et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] M. Piccart,et al. Everolimus Plus Exemestane in Postmenopausal Patients with HR+ Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis , 2013, Advances in Therapy.
[31] M. de Boer,et al. Prognosis of metastatic breast cancer subtypes: the hormone receptor/HER2-positive subtype is associated with the most favorable outcome , 2013, Breast Cancer Research and Treatment.
[32] A. Richardson,et al. Interobserver concordance in implementing the 2010 ASCO/CAP recommendations for reporting ER in breast carcinomas: a demonstration of the difficulties of consistently reporting low levels of ER expression by manual quantification. , 2013, American journal of clinical pathology.
[33] P. Neven,et al. Patient-reported physical, emotional, and social functioning in advanced breast cancer: Insights from BOLERO-2. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[34] A. Howell,et al. Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentre, phase 3 randomised trial. , 2013, The Lancet. Oncology.
[35] R. Greil,et al. The predictive impact of body mass index on the efficacy of extended adjuvant endocrine treatment with anastrozole in postmenopausal patients with breast cancer: an analysis of the randomised ABCSG-6a trial , 2013, British Journal of Cancer.
[36] H. Iwata,et al. A randomized, double-blind, controlled study of exemestane versus anastrozole for the first-line treatment of postmenopausal Japanese women with hormone-receptor-positive advanced breast cancer , 2013, Breast Cancer Research and Treatment.
[37] M. Cristofanilli,et al. Phase II randomized study of the EGFR, HER2, HER3 signaling inhibitor AZD8931 in combination with anastrozole (A) in women with endocrine therapy (ET) naive advanced breast cancer (MINT). , 2013 .
[38] G. Lopes,et al. Anastrozole in combination with fulvestrant in the first line treatment of hormone receptor positive advanced breast cancer: A meta-analysis. , 2013 .
[39] S. Duffy,et al. Comparative efficacy of everolimus versus fulvestrant for hormone-receptor–positive (HR+) advanced breast cancer (ABC) following progression/recurrence after first-line treatment: A network meta-analysis. , 2013 .
[40] G. Pond,et al. Randomized phase II placebo-controlled trial of fulvestrant plus vandetanib in postmenopausal women with bone only or bone predominant, hormone receptor-positive metastatic breast cancer (MBC): OCOG Zamboney study—NCT00811369. , 2013 .
[41] M. Bani,et al. Shared decision-making in metastatic breast cancer: discrepancy between the expected prolongation of life and treatment efficacy between patients and physicians, and influencing factors , 2013, Breast Cancer Research and Treatment.
[42] Bohuslav Melichar,et al. Randomized phase II, double-blind, placebo-controlled study of exemestane with or without entinostat in postmenopausal women with locally recurrent or metastatic estrogen receptor-positive breast cancer progressing on treatment with a nonsteroidal aromatase inhibitor. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[43] G. Lopes,et al. A meta-analysis of anastrozole in combination with fulvestrant in the first line treatment of hormone receptor positive advanced breast cancer , 2013, Breast Cancer Research and Treatment.
[44] J. Jansen,et al. Progression-free survival with fulvestrant 500 mg and alternative endocrine therapies as second-line treatment for advanced breast cancer: a network meta-analysis with parametric survival models. , 2013, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[45] J. Robertson,et al. Ganitumab with either exemestane or fulvestrant for postmenopausal women with advanced, hormone-receptor-positive breast cancer: a randomised, controlled, double-blind, phase 2 trial. , 2013, The Lancet. Oncology.
[46] S. Ohno,et al. Efficacy of goserelin plus anastrozole in premenopausal women with advanced or recurrent breast cancer refractory to an LH-RH analogue with tamoxifen: Results of the JMTO BC08-01 phase II trial , 2013, Oncology reports.
[47] L. Chow,et al. Randomized phase III placebo-controlled trial of letrozole plus oral temsirolimus as first-line endocrine therapy in postmenopausal women with locally advanced or metastatic breast cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[48] K. Gelmon. AUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST , 2013 .
[49] R. Wu,et al. Effects of toremifene versus tamoxifen on breast cancer patients: a meta-analysis , 2013, Breast Cancer.
[50] A. Leo,et al. Final analysis of overall survival for the Phase III CONFIRM trial: fulvestrant 500 mg versus 250 mg , 2012 .
[51] M. Ellis,et al. Fulvestrant 500 mg versus anastrozole 1 mg for the first-line treatment of advanced breast cancer: follow-up analysis from the randomized ‘FIRST’ study , 2012, Breast Cancer Research and Treatment.
[52] A. Thompson,et al. Tissue confirmation of disease recurrence in breast cancer patients: pooled analysis of multi-centre, multi-disciplinary prospective studies. , 2012, Cancer treatment reviews.
[53] I. Ray-Coquard,et al. Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[54] Robert B Livingston,et al. Combination anastrozole and fulvestrant in metastatic breast cancer. , 2012, The New England journal of medicine.
[55] A. Kurian,et al. Age-specific incidence of breast cancer subtypes: understanding the black-white crossover. , 2012, Journal of the National Cancer Institute.
[56] J. Bergh,et al. FACT: an open-label randomized phase III study of fulvestrant and anastrozole in combination compared with anastrozole alone as first-line therapy for patients with receptor-positive postmenopausal breast cancer. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[57] Mark Clemons,et al. Prospective study evaluating the impact of tissue confirmation of metastatic disease in patients with breast cancer. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[58] M. Piccart,et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. , 2012, The New England journal of medicine.
[59] M. Beckmann,et al. Higher efficacy of letrozole in combination with trastuzumab compared to letrozole monotherapy as first-line treatment in patients with HER2-positive, hormone-receptor-positive metastatic breast cancer - results of the eLEcTRA trial. , 2012, Breast.
[60] Martin Krapcho,et al. SEER Cancer Statistics Review, 1975–2009 (Vintage 2009 Populations) , 2012 .
[61] A. Ruíz,et al. Exemestane versus anastrozole as front‐line endocrine therapy in postmenopausal patients with hormone receptor‐positive, advanced breast cancer , 2012, Cancer.
[62] P. Ubel,et al. Helping patients decide: ten steps to better risk communication. , 2011, Journal of the National Cancer Institute.
[63] Ling Li,et al. Aromatase inhibitor versus tamoxifen in postmenopausal woman with advanced breast cancer: a literature-based meta-analysis. , 2011, Clinical breast cancer.
[64] H. Iwata,et al. Three dose regimens of fulvestrant in postmenopausal Japanese women with advanced breast cancer: results from a double-blind, phase II comparative study (FINDER1). , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.
[65] A. Thompson,et al. Prospective comparison of switches in biomarker status between primary and recurrent breast cancer: the Breast Recurrence In Tissues Study (BRITS) , 2010, Breast Cancer Research.
[66] L. Pusztai,et al. Estrogen and HER-2 receptor discordance between primary breast cancer and metastasis. , 2010, The oncologist.
[67] M. Dowsett,et al. Suppression of ovarian function in combination with an aromatase inhibitor as treatment for advanced breast cancer in pre-menopausal women. , 2010, European journal of cancer.
[68] M. Lichinitser,et al. Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[69] V. Valero,et al. Phase II trial of anastrozole plus goserelin in the treatment of hormone receptor-positive, metastatic carcinoma of the breast in premenopausal women. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[70] P. Neven,et al. Results of a phase II study comparing three dosing regimens of fulvestrant in postmenopausal women with advanced breast cancer (FINDER2) , 2010, Breast Cancer Research and Treatment.
[71] S. Franco,et al. Lapatinib plus Letrozole as First-Line Therapy for HER-2+ Hormone Receptor–Positive Metastatic Breast Cancer , 2010, The oncologist.
[72] Bing-he Xu,et al. Fulvestrant 250 mg versus anastrozole for Chinese patients with advanced breast cancer: results of a multicentre, double-blind, randomised phase III trial , 2010, Cancer Chemotherapy and Pharmacology.
[73] Thomas J. Smith,et al. 美国临床肿瘤学会Ⅳ期非小细胞肺癌化疗的临床实践指南更新 , 2010, Zhongguo fei ai za zhi = Chinese journal of lung cancer.
[74] J. Mackey,et al. Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[75] Saeed Sadeghi,et al. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[76] M. Ellis,et al. Lower-dose vs high-dose oral estradiol therapy of hormone receptor-positive, aromatase inhibitor-resistant advanced breast cancer: a phase 2 randomized study. , 2009, JAMA.
[77] V. Georgoulias,et al. Fulvestrant in the treatment of advanced breast cancer: A systematic review and meta-analysis of randomized controlled trials. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[78] M. Piccart,et al. Phase III study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women: the European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[79] J. Baselga,et al. The role of hormonal therapy in the management of hormonal-receptor-positive breast cancer with co-expression of HER2 , 2008, Nature Clinical Practice Oncology.
[80] M. Piccart,et al. Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[81] K. Pritchard. Combining endocrine agents with chemotherapy: Which patients and what sequence? , 2008, Cancer.
[82] L. Gibson,et al. Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women. , 2007, The Cochrane database of systematic reviews.
[83] Anthony Rhodes,et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. , 2006, Archives of pathology & laboratory medicine.
[84] H. Yamashita,et al. Immunohistochemical evaluation of hormone receptor status for predicting response to endocrine therapy in metastatic breast cancer , 2006, Breast cancer.
[85] N. Lurie,et al. Racial and Ethnic Disparities in Care: The Perspectives of Cardiologists , 2005, Circulation.
[86] Phyllis N Butow,et al. Cancer patient preferences for communication of prognosis in the metastatic setting. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[87] J. Forbes,et al. An individual patient-based meta-analysis of tamoxifen versus ovarian ablation as first line endocrine therapy for premenopausal women with metastatic breast cancer , 1997, Breast Cancer Research and Treatment.
[88] D. Ghersi,et al. Chemotherapy alone versus endocrine therapy alone for metastatic breast cancer. , 2003, The Cochrane database of systematic reviews.
[89] P. Butow,et al. Communicating prognosis to patients with metastatic disease: what do they really want to know? , 2002, Supportive Care in Cancer.
[90] C. Boni,et al. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[91] R. Blamey,et al. Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[92] J. Robertson,et al. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[93] A. Buzdar,et al. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[94] J. Klijn,et al. Combined treatment with buserelin and tamoxifen in premenopausal metastatic breast cancer: a randomized study. , 2000, Journal of the National Cancer Institute.
[95] G. Sledge,et al. Comparison of chemotherapy with chemohormonal therapy as first-line therapy for metastatic, hormone-sensitive breast cancer: An Eastern Cooperative Oncology Group study. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[96] D. Berry,et al. Dose-response trial of megestrol acetate in advanced breast cancer: cancer and leukemia group B phase III study 8741. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[97] S. Martino,et al. Multicenter randomized clinical trial of goserelin versus surgical ovariectomy in premenopausal patients with receptor-positive metastatic breast cancer: an intergroup study. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[98] A. Howell,et al. Response after withdrawal of tamoxifen and progestogens in advanced breast cancer. , 1992, Annals of oncology : official journal of the European Society for Medical Oncology.
[99] N. Dubrawsky. Cancer statistics , 1989, CA: a cancer journal for clinicians.
[100] J. Ingle,et al. Randomized trial of bilateral oophorectomy versus tamoxifen in premenopausal women with metastatic breast cancer. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.